In summary, PD-L1 expression on immune cells is a key indicator of a pre-existing anti-tumor adaptive immune response, and its presence is associated with enhanced therapeutic effects in HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.